<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451776</url>
  </required_header>
  <id_info>
    <org_study_id>0608119</org_study_id>
    <secondary_id>2006-007017-21</secondary_id>
    <nct_id>NCT00451776</nct_id>
  </id_info>
  <brief_title>Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC</brief_title>
  <official_title>Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC. A Prospective, Monocentric, Randomised Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of its hemodynamic safety, etomidate is widely used for anaesthesia induction of&#xD;
      cardiac surgery. It can also cause adrenal insufficiency during the following 48 hours ( 11&#xD;
      betahydroxylase inhibition ). So it could increase hemodynamic dysfunction caused by the SIRS&#xD;
      following cardiopulmonary bypass.&#xD;
&#xD;
      A previous observational study found more adrenal insufficiency and need for vasopressive&#xD;
      support therapy in the etomidate group versus another propofol induced group.&#xD;
&#xD;
      The aim of our work is to compare hemodynamic dysfunction following induction with etomidate&#xD;
      for cardiac surgery with ECC. The control group would be induced by Propofol. 94 patients&#xD;
      would be included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Information will be given at the anaesthetic consultation, few weeks before planed cardiac&#xD;
      surgery. Eligibility and exclusion criteria will be checked. Patient will receive an&#xD;
      informative written consent notice and all questions will be answered. A standard&#xD;
      pre-operative blood collection will be sampled.&#xD;
&#xD;
      In order to minimize the potential confusing effect of daily cortisol variation, only&#xD;
      surgical procedure performed early morning will be considered. The day before surgery&#xD;
      definitive inclusion will be decided as the order of procedure is not known before. Only&#xD;
      patients operated in the morning will be included because of cortisol daily variations. At&#xD;
      this time, consent and information notice will be signed and checked in the medical record.&#xD;
&#xD;
      On the morning of surgery, during venous catheter insertion an additional blood sample will&#xD;
      be collected to asses basal cortisolemia.&#xD;
&#xD;
      Randomisation will be carried out centrally after patient operative theatre admission, by&#xD;
      phone call from ICU to randomisation office. Hypnotic drug will be prepared in the ICU&#xD;
      department next to the operative room and blindly administered to patient ( same volume per&#xD;
      weight ). All other anesthetic procedures will be standardised : opioid drugs, vasopressive&#xD;
      support, antifibrinolytics and hemodynamic monitoring.&#xD;
&#xD;
      After surgery patients are admitted to surgical ICU. They will undergo standard post&#xD;
      operative exams plus two corticotrophin tests and a dosage of SIRS markers ( IL6 and TNF&#xD;
      alpha ). These results will only be known at the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to discharge to vasoactive supportive therapy in the first 48 post operative hours .</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic supportive drugs ( I .e : dodutamine and noradrenaline ) doses at different time .</measure>
    <time_frame>several times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systematic inflammatory response intensity</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic supportive drugs consumption in patients with SIRS sub group</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction incidence in the first 48 postoperative hours .</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital mortality</measure>
    <time_frame>day of hospital coming out</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who received etomidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who received propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etomidate</intervention_name>
    <description>patients who received etomidate</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>patients who received propofol</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age superior to 18 years&#xD;
&#xD;
          -  patient which had to be operated for aorto-coronary pass and/or valvular replacement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with aortics shrinking&#xD;
&#xD;
          -  women pregnant or nursing&#xD;
&#xD;
          -  contra-indication to etomidate or diprivan or synacthene&#xD;
&#xD;
          -  patient with insufficiency kidney&#xD;
&#xD;
          -  patient with infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérome MOREL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Saint Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>March 22, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <last_update_submitted>October 29, 2008</last_update_submitted>
  <last_update_submitted_qc>October 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Jérôme MOREL</name_title>
    <organization>Centre Hospitalier Universitaire de Saint Etienne</organization>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>adrenal insufficiency</keyword>
  <keyword>etomidate</keyword>
  <keyword>propofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Etomidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

